ATXS
Price
$5.89
Change
+$0.19 (+3.33%)
Updated
Jun 18 closing price
Capitalization
321.68M
53 days until earnings call
CLDX
Price
$20.82
Change
+$0.76 (+3.79%)
Updated
Jun 18 closing price
Capitalization
1.38B
49 days until earnings call
Interact to see
Advertisement

ATXS vs CLDX

Header iconATXS vs CLDX Comparison
Open Charts ATXS vs CLDXBanner chart's image
Astria Therapeutics
Price$5.89
Change+$0.19 (+3.33%)
Volume$373.67K
Capitalization321.68M
Celldex Therapeutics
Price$20.82
Change+$0.76 (+3.79%)
Volume$745.71K
Capitalization1.38B
ATXS vs CLDX Comparison Chart in %
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. CLDX commentary
Jun 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and CLDX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 19, 2025
Stock price -- (ATXS: $5.89 vs. CLDX: $20.82)
Brand notoriety: ATXS and CLDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 74% vs. CLDX: 78%
Market capitalization -- ATXS: $321.68M vs. CLDX: $1.38B
ATXS [@Biotechnology] is valued at $321.68M. CLDX’s [@Biotechnology] market capitalization is $1.38B. The market cap for tickers in the [@Biotechnology] industry ranges from $335.78B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileCLDX’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • CLDX’s FA Score: 0 green, 5 red.
According to our system of comparison, ATXS is a better buy in the long-term than CLDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 6 TA indicator(s) are bullish while CLDX’s TA Score has 5 bullish TA indicator(s).

  • ATXS’s TA Score: 6 bullish, 4 bearish.
  • CLDX’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, CLDX is a better buy in the short-term than ATXS.

Price Growth

ATXS (@Biotechnology) experienced а +1.73% price change this week, while CLDX (@Biotechnology) price change was +1.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.32%. For the same industry, the average monthly price growth was +13.75%, and the average quarterly price growth was +8.90%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

CLDX is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+7.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLDX($1.38B) has a higher market cap than ATXS($322M). CLDX YTD gains are higher at: -17.610 vs. ATXS (-34.116). ATXS has higher annual earnings (EBITDA): -124.4M vs. CLDX (-213.94M). CLDX has more cash in the bank: 673M vs. ATXS (295M). CLDX has less debt than ATXS: CLDX (3.43M) vs ATXS (5.06M). CLDX has higher revenues than ATXS: CLDX (7.56M) vs ATXS (0).
ATXSCLDXATXS / CLDX
Capitalization322M1.38B23%
EBITDA-124.4M-213.94M58%
Gain YTD-34.116-17.610194%
P/E RatioN/AN/A-
Revenue07.56M-
Total Cash295M673M44%
Total Debt5.06M3.43M148%
FUNDAMENTALS RATINGS
ATXS vs CLDX: Fundamental Ratings
ATXS
CLDX
OUTLOOK RATING
1..100
2257
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
55
Fair valued
PROFIT vs RISK RATING
1..100
10065
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
5063
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLDX's Valuation (55) in the Biotechnology industry is in the same range as ATXS (59). This means that CLDX’s stock grew similarly to ATXS’s over the last 12 months.

CLDX's Profit vs Risk Rating (65) in the Biotechnology industry is somewhat better than the same rating for ATXS (100). This means that CLDX’s stock grew somewhat faster than ATXS’s over the last 12 months.

CLDX's SMR Rating (94) in the Biotechnology industry is in the same range as ATXS (97). This means that CLDX’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's Price Growth Rating (50) in the Biotechnology industry is in the same range as CLDX (63). This means that ATXS’s stock grew similarly to CLDX’s over the last 12 months.

ATXS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CLDX (100). This means that ATXS’s stock grew similarly to CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSCLDX
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
N/A
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GBLCX38.980.03
+0.08%
American Funds Global Balanced C
IRMAX9.32N/A
N/A
Voya Russell Mid Cap Index Port A
GAONX20.69N/A
N/A
JPMorgan Global Allocation R2
TSLRX4.66N/A
N/A
Transamerica Small Cap Value R6
FGILX22.45N/A
N/A
Fidelity Global Equity Income

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with KYMR. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+3.33%
KYMR - ATXS
53%
Loosely correlated
+0.19%
XENE - ATXS
53%
Loosely correlated
+0.63%
COGT - ATXS
53%
Loosely correlated
-4.99%
TRDA - ATXS
53%
Loosely correlated
-5.13%
CRNX - ATXS
53%
Loosely correlated
-1.13%
More

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with BEAM. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
+3.79%
BEAM - CLDX
53%
Loosely correlated
+1.92%
ATXS - CLDX
50%
Loosely correlated
+3.33%
CRNX - CLDX
50%
Loosely correlated
-1.13%
RVMD - CLDX
50%
Loosely correlated
+2.02%
DNLI - CLDX
49%
Loosely correlated
-3.63%
More